NFKB1 and hepatocellular carcinoma: In hepatocellular carcinoma, Lo et al. demonstrated that NF-κB-mediated up-regulation of CD47 promoted sorafenib resistance, and they proposed a CD47 targeted therapy in combination with sorafenib as a novel therapeutic regimen for hepatocellular carcinoma [39].